GenEdit is sailing toward the clinic with a new name and fresh funding.  | GenEdit is sailing toward the clinic with a new name and fresh funding. Rebranded as BreezeBio, the biotech has raised $60 ...

Novartis is wasting little time sketching out the radiopharmaceutical details of its $23 billion U.S. investment push. | Novartis is wasting little time sketching out the radiopharmaceutical details ...

A coalition of 15 states is filing a lawsuit against Robert F. Kennedy Jr. | A coalition of 15 states is filing a lawsuit against Robert F. Kennedy Jr. and the Centers for Disease Control and ...

Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price. | ...

AstraZeneca is giving Pascal Soriot a pay raise as the longtime CEO weathered a year of “significant geopolitical uncertainty ...

Still, broad uptake has long been an uphill battle for the gene therapy as it competes with a variety of treatments including, Roche’s blockbuster Hemlibra, Sanofi’s newer sales driver Altuviiio and ...

Four years after the FDA issued its most heavy-handed form of a rejection to the prior company behind pegzilarginase, the U.S. regulator has now given the treatment a thumbs-up. | Four years after the ...

The agreement ends litigation between the Swiss company and the estate of Henrietta Lacks, which filed a lawsuit in federal court in Baltimore against Novartis and Viatris in August 2024. The family ...

Roche’s autoimmune drug Enspryng is making solid progress as a treatment for neuromyelitis optica spectrum disorder (NMOSD).

At least one major partner has pumped the brakes on a deal that the president’s import taxes helped facilitate last summer.

More recently, Pfizer splashed out $150 million upfront—and put up hundreds of millions more in potential milestones—to acquire worldwide rights to a GLP-1 agonist dubbed YP05002 from Yao Pharma, a ...

Indivior has picked Havas as its primary partner for engaging healthcare professionals and patients in the U.S.  | Havas will lead Indivior’s integrated strategy, creative, media and digital efforts ...